who were also members of the IUPAC subcommittee on drug discovery: Gioavanni Gaviraghi described the story of lacidipine, a calcium antagonist. Joerg Senn-Bilfinger wrote a chapter on the discovery of pantoprazole, a proton-pump inhibitor. Rudolf Wiechert summarized the discovery of drospirenone. Pa...
The plaintiffs of the class-action lawsuit allege that Rexulti causes compulsive behaviours and impulse control disorders, including compulsive gambling, hypersexuality, compulsive shopping and binge eating. They claim that the makers of the drug — Otsuka Canada Pharmaceutical Inc. and Lundbeck Canada ...
Otsuka and Lundbeck announce the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) of REXULTI® (brexpiprazole) for the treatment of schizophrenia in pediatric patients 13 to 17 years of age. The FDA prev
Inc.(Otsuka) and H. Lundbeck A/S (Lundbeck) announce the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) of REXULTI®(brexpiprazole) for the treatment of schizo...
headache, dizziness, urinary tract infection, nasopharyngitis, and sleep disturbances (both somnolence and insomnia). Rexulti will retain the Boxed Warning for medications in this class that elderly patients with dementia-related psychosis treated with antipsychotic drugs are at a...
Overview:Rexulti, which is currently indicated for use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder in adults and for the treatment of schizophrenia in adult and pediatric patients aged 13 years and older, received approval by the Food and Drug Administra...
Olanzapine belongs to a drug class known as atypical antipsychotics. Other members of this class includeclozapine(Clozaril),risperidone(Risperdal),aripiprazole(Abilify) andziprasidone(Geodon). The exact mechanism of action of olanzapine is not known. It may work by blocking receptors for several neuro...
Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) report that the U.S. Food and Drug Administration (FDA) has accepted a Supplemental New Drug Application (sNDA) for the treatment of schizophrenia in ...
(including fatal cases) has been reported with other agents in this class. Monitor complete blood count in patients with pre-existing low white blood cell count (WBC)/absolute neutrophil count or history of drug-induced leukopenia/neutropenia. Discontinue REXULTI at the first sign ...